A Phase I, Randomized, Open-label, Single Dose, 2 Period, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Linerixibat Tablets in Healthy Adult Participants
Latest Information Update: 01 Dec 2022
Price :
$35 *
At a glance
- Drugs Linerixibat (Primary)
- Indications Cholestasis; Pruritus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 24 Nov 2022 Status changed from not yet recruiting to completed.
- 30 Jun 2022 New trial record